Kura’s $150M PIPE; Lilly’s investment in Prism BioLab; Annovis delays PhIII data, citing ‘data cleaning’

Plus, news about IMU Biosciences, ZWI Therapeutics and Sagimet Biosciences:

Kura Oncology’s $150M PIPE: The biotech is raising funds from a stock sale to its existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital Management. It’s selling at $17.25 a share, a…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks